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Abstract: Candida auris is an enigmatic yeast that continues to stimulate interest within the mycology 
community due its rapid and simultaneous emergence of distinct clades. In the last decade, almost 
400 manuscripts have contributed to our understanding of this pathogenic yeast. With dynamic 
epidemiology, elevated resistance levels and an indication of conserved and unique pathogenic 
traits, it is unsurprising that it continues to cause clinical concern. This mini-review aims to 
summarise some of the key attributes of his remarkable pathogenic yeast. 
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1. Introduction 
A decade on since its discovery, Candida auris has rapidly emerged as a significant nosocomial 
pathogen, responsible for an escalating number of infections across the globe. C. auris possesses some 
almost unique characteristics for an infectious yeast in that it can survive and persist within the 
environment for prolonged periods and a significant number of clinical isolates have been reported 
to be multi-drug resistant, with a very small proportion resistant to three classes of antifungals [1]. 
The simultaneous emergence of genetically unrelated clades of this organism has sparked thoughts 
as to how this drug resistant yeast originally manifested, with only just recently theories being 
proposed on its emergence, linked to some novel biological traits, which will be discussed in this 
review [2,3]. 
2. Clinical and Epidemiological Basis of Disease 
To date, 39 countries have reported documented cases of C. auris infection, with clinical case 
reports from all inhabited continents. The first clinical report was from an isolate from an ear canal 
in 2009 in Japan [4], with 15 other ear isolates detected in the same year in South Korea [5,6]. These 
initial reports indicated an uncommon fungal infection that was predominantly limited to ear 
isolates. In 2011, the first candidemia cases were described in South Korea, one of which dated back 
to 1996 [7]. Since then, invasive infections, especially candidemia, have increased [8]. The emergence 
of C. auris has changed candidemia epidemiology in certain countries, even outcompeting the most 
common fungal pathogen Candida albicans at a number of centers in South Africa [9-13]. Additionally, 
outbreaks continuing for months have been described, sometimes resulting in the closing of intensive 
care units [10,14,15]. Given the initial and continuing difficulty in correctly identifying C. auris, the 
extent and overall burden of the problem might be underestimated [8,16-20]. 
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Perhaps the most fascinating insight into C. auris was the discovery of the simultaneous 
emergence of genetically unrelated clonal populations across three different continents. This 
pioneering discovery from Lockhart and colleagues revealed through whole genome sequencing that 
four independent clades existed. These clades appeared to be geographically specific and are 
commonly classified as South Asian (clade I), East Asian (clade II), African (clade III), and South 
American (clade IV) clades, and differ by tens of thousands of single nucleotide polymorphisms 
(SNPs), with minimal genetic intra-clade differences (<60 SNPs) [1]. Interestingly, a recent study has 
suggested a potential fifth C. auris clade from an ear swab isolate of an Iranian patient. The patient 
had no documented travel history, suggesting that this emergence of C. auris may have not been a 
recent introduction. Despite being pathologically similar to the East Asian clade, this isolate was 
hundreds of thousand SNPs different than this and the other three clades [21]. The stimuli for the 
unique emergence of C. auris are not well understood, with suggestions of anthropogenic factors 
playing a contributing role.  
3. Is Candida auris a Virulent Pathogen? 
As our clinical knowledge of C. auris has expanded, we have sought in parallel to understand 
why this yeast is portrayed as such a successful pathogen. With a somewhat limited molecular 
understanding of C. auris, details are now beginning to emerge in the literature to shine a light on 
key elements of its virulence profile. 
The first description resembling the basis of a virulent phenotype appeared in 2015, when simple 
experimental approaches described the expression of phospholipase, proteinase and hemolysin 
activity [22]. Next, some more detailed studies from Borman and colleagues (2016) reported 
differential growth rates and release of daughter cells that manifested itself as an aggregating 
phenotype, which was less virulent than non-aggregating cells [23]. This study was the foundation 
for the first definitive study detailing its ability to differentially form antifungal tolerant biofilms [24]. 
Interestingly, a more recent study has identified that cellular aggregation is in fact an inducible 
phenomenon that can be triggered by sub-inhibitory concentrations of triazole and echinocandin 
antifungals [25]. Collectively, these laboratory studies, and confirmatory analyses [26], highlighted 
the pathogenic potential of C. auris. Moreover, utilising C. albicans as a comparator species has helped 
improve our overall understanding and expand our capabilities to investigate this resilient and 
tolerant yeast [27,28]. 
An advantage of C. auris coming ‘late to the party’ is that genomic technologies and the use of 
comparator species have supported finding orthologues of proteins well-characterised in C. albicans. 
The first study to do so came from India, where Chaterjee and colleagues (2015) reported that it 
shared significant virulence attributes, including mannosyl transfersases, oligopeptide transporters, 
secreted proteases and genes involved in biofilm formation [29]. These observations support the 
aforementioned laboratory studies; however, a limitation to these data are that many genes encoded 
hypothetical and undefined proteins. How do we determine the functionality and relative 
importance of these, or do we simply discount these? More robust studies that have followed 
substantiated these observations, including multiple genes encoding drug transporters, secreted 
aspartyl proteinases and lipases [30]. One way this has been approached is through using 
transcriptomics data sets. We were able to undertake a de novo transcriptome assembly that was 
assembled into an approximately 11.5Mb transcriptome, consisting of 5848 genes [31]. Here, a 
number of important transcripts were differentially expressed, particularly adhesins IFF4 and CSA1, 
ALS-gene family members, and other biofilm related genes, such as secreted aspartyl protease and 
extra-cellular matrix related components. More recently, it has been reported through the use of 
multi-omics approaches that in comparison to C. albicans, C. auris exhibits significant differences in 
carbon utilisation and downstream cellular protein and lipid content [32]. It is likely that further 
pathogenic insights will begin to emerge as large scale data-sets are produced. This intensified effort 
will enable us to fully comprehend why this yeast can be so damaging to patients. 
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4. Stress Responses and Key Signaling Pathways of Candida auris 
Survival strategies and adaptation to multiple ecological niches are prerequisites for many 
successful pathogens. Some of the defining features of C. auris are its high temperature and salt 
tolerance, which can permit survival in harsh environments [33]. At 37 °C and 40 °C, C. auris grows 
comparatively with C. albicans; temperatures at which the more genetically similar Candida haemulonii 
struggles, or cannot grow. Additionally, a number of C. auris isolates have been shown to grow at 
temperatures as high as 42 °C, which inhibits C. albicans growth [34]. This organism also demonstrates 
high salinity tolerance, growing at 10% wt/vol, a potential factor in being able to quickly and more 
readily detect and culture this pathogen [35]. Interestingly, these elevated salt concentrations can 
induce the formation of elongated cell morphologies, similar to pseudohyphae of other Candida spp 
[36]. However, the biological mechanisms and significance of this morphogenic switching remain to 
be elucidated. 
Adaptation to environmental and host responses are typically controlled by a variety of 
different, conserved signaling pathways across many pathogenic fungi. Studies understanding the 
functions of such pathways in C. auris are still well within their infancy; however, some studies have 
begun to elucidate these functions. One such key stress response is the Hog1-related stress-activated 
protein kinase (SAPK) signaling pathway. Using hog1Δ strains, Day et al. (2018) demonstrated 
multiple functions for SAPK in resistance to environmental stressors such as H2O2 and osmotic stress 
[37]. Interestingly, the hog1Δ strain displayed attenuated virulence compared to the wild type, which 
could be as a result of the mutant forming large aggregates, which has been observed in clinical 
isolates that are less virulent than non-aggregating counterparts [23,24]. In line with these previous 
studies on aggregation, the SAPK pathway could be significant in the formation of aggregates as a 
potential survival strategy. Other key stress response pathways are dependent on the protein 
phosphatase calcineurin, which interacts with the molecular chaperone protein HSP90. Analysis of 
protein function of Hsp90 in C. auris has been shown to have multiple roles and essential for growth 
[38]. Interestingly, Hsp90 was shown to negatively regulate filamentation in C. auris, with inhibition 
of Hsp90 resulting in elongated pseudohyphae-like structures, morphologically similar to those 
induced by high salinity and passage through mammalian hosts [36,39]. Furthermore, its inhibition 
was shown to increase fluconazole susceptibility of two C. auris isolates to which did not harbor any 
common ERG11 mutations related to azole resistance [38]. 
The organisms’ ability to survive in these typically microbe-unfavorable conditions are said to 
be key factors in the recently proposed climate change hypothesis by Casadevall and colleagues, and 
its transition from being a previously unknown environmental yeast to a significant nosocomial 
pathogen, with its potential intermediate transmission through an avian host [2]. The authors of this 
study provide a tantalising hypothesis that higher ambient environmental changes brought about by 
human intervention has led to the selection of thermally tolerant fungal species that can infringe upon 
the protective thermal restriction zone. The thermal restriction zone, i.e., the temperature differential 
between the high protective basal temperatures of mammals and that of ambient environmental 
temperatures, may be narrowing as a result of climate change. Casadevall and colleagues (2019) 
undertook comparative analysis of the C. auris and closely related relative species, demonstrating 
that these were not generally thermotolerant to mammalian temperatures [2], indicating that they 
have not evolved as human pathogens. We know that C. auris constitutively overexpresses heat shock 
protein 90, and by borrowing knowledge from other Candida pathogens we can surmise that this may 
account for its virulence, thermal tolerance, osmotic-stress tolerance and multidrug resistance. These 
ideas taken together, and with caution until we have definitive evidence, allow us to postulate that 
C. auris is an environmental yeast that has made the opportunistic leap to human hosts. It 
preferentially locates and persists on the cooler and salty environments of the skin, even with the 
capacity to form tolerant biofilms structures [40]. Intriguingly, could it be that aqueous and salty 
environments of wetlands and marshes are more prone to climatic change, and this has propelled C. 
auris success? Alternatively, could the drivers for this emergent pathogen have a simpler explanation, 
propelled by an ecotoxicological threat of high-level of azole antifungals found in our own 
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wastewater [41]? Irrespectively, whether one or a combination of these theories is correct, it is highly 
likely that the emergence of C. auris is a human-made phenomenon. 
5. Biofilms and Surfaces 
A key pathogenicity mechanism of various Candida spp. is the formation of highly organised and 
structured communities known as biofilms. The ability of clinical isolates to form biofilms has been 
identified as a significant risk factor negatively associated with patient outcomes for both C. albicans 
and Candida parapsilosis [42,43], as well as other species, such as Candida glabrata, frequently isolated 
from indwelling medical devices [44]. To date, there are limited studies detailing the clinical 
significance of C. auris biofilms with regards to risk factors for invasive disease. Isolates have however 
been recovered from a number of clinical sites including wounds, stents, temperature probes and 
central lines, suggestive of a biofilm-related lifestyle in host [14,34,45]. 
Biofilm formation was initially disregarded in a study using isolates from the East Asian clade 
[6]. Interestingly, this clade appears to display some unique behavioral patterns in comparison to 
other clades, including lower fluconazole resistance rates and high incidence of causing otitis [46]. In 
addition, these isolates rarely cause invasive infections and large-scale outbreaks, which could 
explain the inability of these organisms to form biofilms [47]. A number of studies have started to 
look at the implications of C. auris biofilms, particularly with regards to drug tolerance [31,48-50]. 
These studies have shown that various C. auris isolates can selectively tolerate clinically significant 
concentrations of all three classes of antifungals. 
Biofilm tolerance mechanisms employed by this emerging pathogen appear analogous as to 
those of C. albicans, the primary biofilm forming pathogen within the genus. Using a temporal 
transcriptomic analysis of various stages of biofilm, our group characterised the key processes which 
govern biofilm formation and its associated increased antifungal tolerance. Efflux pumps of both ATP 
binding cassette and major facilitator superfamily transporters, were up-regulated as the biofilm 
matured to 24 hours of growth compared to planktonic cells [31]. It remains unknown as to whether 
a C. auris biofilm cell is more virulent compared to an equivalent planktonic cell, as was shown with 
C. albicans [51]. Given that gene expression of the hydrolytic enzymes PLB3 and SAP5 were also up-
regulated in biofilm cells within our data-set, then it would be plausible that they indeed may be 
more virulent and invasive [31]. Another key component of fungal biofilms is the formation of the 
extracellular matrix (ECM) [52]. Like other biofilm tolerance mechanisms, the composition and 
function of the C. auris biofilm matrix appears to be conserved with other Candida spp [53]. Using 
radiolabelled fluconazole, the authors demonstrated that this protective substrate is able to sequester 
between 50% and 90% of available fluconazole within the matrix, rendering the drug unable to reach 
its target. In addition, physical removal and chemical degradation of individual polysaccharides of 
the matrix significantly increasing the susceptibility of these communities to fluconazole [53]. Under 
biofilm-inducing conditions, mass-spectrometry analysis identified significant quantities of tyrosol 
in the supernatant, a quorum sensing molecule involved in C. albicans biofilm formation, suggesting 
another potentially conserved biofilm function [54].  
In addition to reducing the susceptibility to antifungal drugs, it has been speculated that C. auris 
biofilms may have an environmental function in facilitating nosocomial survival and persistence. The 
formation of environmental biofilms has been proposed as survival mechanism for a number of 
microbial pathogens, most notably Staphylococcus aureus [55]. These communities are thought to play 
a key role in hospital acquired infections and can remain viable for multiple weeks, tolerate 
commonly used disinfection procedures and can subsequently transmit to other surfaces. In 
laboratory-based studies, C. auris has demonstrated all of these characteristics surviving on various 
abiotic substrates such as plastic and steel as long as four weeks [35] and also being recovered for 
multiple different fomites in the hospital environments [56]. C. auris demonstrates variable 
susceptibility to a number of disinfection reagents (reviewed in [57]) with studies only recently 
beginning to understand the effects of disinfectants against surface-adherent C. auris cells. Using a C. 
auris dry-surface biofilm model, Ledwoch and Maillard demonstrated that these communities can 
remain viable after certain biocide treatment, and are also able to successfully regrow and transfer to 
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another sterile substrate post disinfection [58]. In addition, Short et al. (2019) showed the up-
regulation of biofilm-related genes after 14 days of environmental survival, including those involved 
in adherence, drug resistance and ECM formation [59]. 
The emerging data in the field appear to support the notion that biofilm biology is an important 
aspect of C. auris lifestyle and going forward this direction of research will likely provide important 
details on its persistence and antifungal tolerance. Indeed, it may also expose some clues to support 
the notion that C. auris is a man-made phenomenon.  
6. In vivo Models of Invasive Candidiasis to Study host–C. auris Interactions 
Integral to understanding the virulence of microbial pathogens is the successful utlisisation of 
in vivo models. Several groups have investigated the pathogenicity of Candida auris in a variety of in 
vivo systems, including invertebrate, fish, and murine models, with key and sometimes conflicting 
findings highlighted in figure 1. Initial studies were performed by Borman and colleagues, using the 
invertebrate moth larvae (Galleria mellonella) model of systemic candidiasis, which was used to 
explore the virulence traits of non-aggregating and aggregating forms of C. auris in vivo [23]. In this 
system, C. auris was found to be as virulent as Candida albicans and Candida tropicalis. This high 
virulence rate is especially important given that C. auris strains do not produce hyphae comparable 
to that of other Candida spp [23]. Our group have corroborated such findings within this G. mellonella 
model, identifying that two non-aggregative C. auris strains possessed enhanced virulence capacity 
over aggregating counterparts, as well as C. albicans at reduced inoculum concentrations [24]. G. 
mellonella provide useful model platforms due to reduced ethical implications, whilst also possessing 
different components of the innate immune system comparable to the mammalian system (reviewed 
in Trevijano-Contador et al., 2018 [60]). Studies have used these models to explore the early cellular 
and humoral responses in G. mellonella following infection with C. albicans [61,62]. Of note, a study 
by Sheehan and Kavanagh (2018) identified a bisphasic response by the larvae to C. albicans infection; 
early response (> 6 hours) is driven by non-specific immune reactions (antimicrobial peptides release 
and melanisation) whilst later stages are characterized by specific responses (increases in haemocyte 
number resulting in larval death) [62]. To our knowledge, studies have yet to examine the host 
response in G. mellonella to C. auris. Future work may warrant such investigations, to fully elucidate 
mechanisms by which C. auris phenotype is driving differential levels of virulence in this model, with 
emphasis on histological changes, alterations in haemocyte number and gene or protein expression 
of key host molecules, such as antimicrobial peptides, opsonins and lysozymes. 
Another invertebrate organism using to study infectious disease is Drosophila melanogaster, 
which has been previously used with fungal pathogens including Candida albicans [63]. Using Toll-
deficient (Tl) D. melanogaster flies, Wurster et al. (2019) demonstrated that 10 C. auris isolates 
representing all four geographical clades were significantly more virulent than a C. albicans isolate 
[64]. Interestingly, and in disagreement with previous studies [23,24], the aggregative capacity of 
isolates had no effect on pathogenicity in D. melanogaster to which the authors hypothesise to be due 
to the impaired phagocytic and immune function in Tl-deficient flies. 
A model of invasive candidiasis using a zebrafish (Danio rerio) system has recently been used to 
visualize the host-pathogen interactions between neutrophils and C. auris in vivo [65]. These in vivo 
systems hold many advantages over invertebrate models, including close similarity in genetics, 
physiology, anatomical structure, and innate and adaptive immune functions with mammalian hosts 
[66]. A number of publications have used the zebrafish model to investigate the roles of macrophages 
and neutrophils in immune defense against a range of fungal species including Aspergillus, Candida 
and Cryptococcus species (reviewed in [67]). Moving forward, examination of the zebrafish host 
response to multiple C. auris strains from various clades with diverse phenotypes is necessary to fully 
elucidate any potential interactions between different C. auris strains and host cells in vivo. 
Recent studies have documented the virulence of C. auris in murine models of invasive 
candidiasis. In a similar manner to observations from G. mellonella models, survival rates in mice post-
infection with C. auris are strain-dependent [34,36,68,69], further affirming that genetic variability 
among the strains collected from diverse geographic locations impacts the organisms virulence. Two 
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comparative virulence studies for multiple Candida species used an immunocompromised murine 
model to show that two C. auris isolates from India, and one isolate from Israel, displayed similar 
virulence to C. albicans strains [34,68]. Conversely, a C. auris isolate from China was non-virulent in a 
BALB/c mouse with normal immune system, whilst all C. albicans-infected mice died within six days 
of infection [36]. Many fungal pathogens including C. auris disproportionally affect 
immunocompromised patients within healthcare settings and as such it is important to characterise 
host-pathogen interactions in models that mimic real-life circumstances. In a study by Xin et al. (2019) 
it was shown that immunocompromised mice were slightly more susceptible to C. auris infection than 
immunocompetent mice [69], suggesting a crucial role for a healthy immune system in controlling C. 
auris virulence. A fascinating observation from histopathological analyses in these candidiasis 
murine studies was that C. auris accumulated in the kidney of the mice in the form of aggregates 
[34,39,68], potentially offering an explanation for the survival and persistence of the organism in vivo. 
In addition, a study by Yue et al. reported that a small percentage of yeast cells isolated from murine 
liver and kidney tissue displayed a filamentous phenotype morphologically similar to hyphae in 
other Candida spp when cultured ex vivo at a low temperature [39]. Passage through a second murine 
host revealed that filamentous cells switched to ‘filamentous competent’ yeast in vivo, but 
maintained their filamentous phenotype ex vivo. Tissue burden studies revealed a higher fungal load 
within the brain and lungs of mice infected with filamentous cells than typical yeast cells, with a skin 
colonisation assay revealing that filamentous cells were capable of invading the underlying 
epidermal tissue of mice with topical skin infection, compared to superficial colonisation by typical 
yeast cells [39]. More recently, a porcine skin model has been reported, where it was shown that C. 
auris had the capacity to proliferate and form multilayer biofilm communities [40]. This is some of 
the most compelling evidence of how it may survive and persist in healthcare environments. Further 
studies are required to assess the host response in tissues and systemically following C. auris 
infection. 
Given the well-documented antifungal resistance rates and limited therapeutic options, murine 
infection models provide key data to better inform prescribing practices for clinical C. auris cases. 
Using neutropenic mice, Lepak et al. (2017) performed pharmacodynamics studies on nine C. auris 
isolates from representative geographical clades and demonstrated the cidal effect of micafungin 
against tested strains, highlighting its use as the first-line therapy for infected patients [70]. 
The use of arthropod, mammalian and invertebrate models in studying C. auris infection from 
each of the various geographical clades has greatly enhanced our understanding of the virulence and 
pathology of this emerging pathogen. There still remains a number of answered questions including 
the underlying biological processes responsible for observed differences in virulence between isolates 
from the varying geographic clades. 
 
Figure 1. Summary of in vivo pathogenicity studies of Candida auris. 
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The virulence of C. auris in comparison to various other Candida spp has been assessed in a number 
of different vertebrate and invertebrate systems including Galleria mellonella (A), immunocompetent 
mice (B), immunocompromised mice (C), Danio rerio (D) and Drosophila melanogaster (E). Figure was 
created with BioRender. 
7. Hide and Seek—Immune Evasion or Lack of Immune Surveillance? 
From the in vivo studies described above, it could be postulated that C. auris uses sophisticated 
mechanisms to evade the immune response and thereby escape expulsion from the host. Indeed, the 
work of Johnson et al. (2018) showed that C. auris were resistant to neutrophil-mediated killing in 
vitro, whilst neutrophils preferentially targeted and engulfed C. albicans in mixed cultures with C. 
auris (Fig2A). In the zebrafish model, 50% less neutrophils were recruited, and a reduced number of 
neutrophil extracellular traps were produced in response to C. auris over C. albicans infection [65]. 
Another study showed that viable C. auris failed to induce a significant inflammatory response in 
human peripheral blood mononuclear cells (PBMCs), whilst live Candida tropicalis, Candida 
guilliermondii and Candida krusei induced a much greater release of TNF-α, IL-6 and IL1-β (Fig2B).  
Conversely, heat-killed organisms, including C. auris, stimulated an elevated production of all pro-
inflammatory mediators [71]. The authors postulated that heat-inactivation resulted in artificial 
exposure of chitin and β1,3-glucan on the surface of the cell wall, leading to a dectin-1 receptor 
stimulation and an elevated immune response as previously described with C. albicans [72]. This 
hypothesis may suggest that the morphological structure and/or aggregative phenotype of C. auris 
could dictate its immunomodulatory effects. Moreover, the same study showed that human 
monocyte-derived macrophages were shown to interact with and phagocytose C. auris (Fig2C), yet 
not to the same efficiency as other Candida species, such as C. tropicalis, C. guilliermondii and C. krusei. 
Therefore, it can be concluded from this study that the host recognizes the organism (e.g., 
macrophage recognition), yet fails to establish an effective immune response against a viable C. auris 
cell (an elevated pro-inflammatory cytokine response). 
Interestingly, a publication by Singh et al. (2019) elegantly showed that vaccination of 
neutropenic BALB/c mice with NDV-3A (a vaccine targeting the N-terminus of Als-3 protein 
formulated with alum) recognized C. auris in vitro and protected immunosuppressed mice from 
otherwise lethal C. auris-disseminated infection [73]. In vitro, the authors found that anti-Als3p 
antibodies generated by the NDV-3A vaccine in the murine model inhibited biofilm formation 
(Fig2D) and enhanced the opsonophagocytic killing of C. auris by macrophages (Fig2E). In vivo, an 
important functional role for macrophage and CD4+ T cells was identified in the NDV-3A vaccination 
mechanism, whereby depletion of these immune cells in the murine model compromised the NDV-
3A vaccine-mediated protection against C. auris (Fig2F) [73]. This is further evidence that C. auris is 
recognised by the immune system under certain physiological conditions. At the time of writing, 
investigations into host-pathogen interactions in C. auris-mediated infection are limited; future 
studies must continue to explore the effects of various C. auris strains on different subsets of the innate 
and adaptive immune system, both in vitro and in vivo. 
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Figure 2. Host-pathogen interactions of Candida auris. 
Candida auris evades neutrophil capture via neutrophil extracellular trap (NET) formation. 
Neutrophils preferentially target Candida albicans in mixed cultures with C. auris (A). Peripheral blood 
mononuclear cells (PBMCs) fail to induce a potent pro-inflammatory cytokine response against C. 
auris, whilst Candida tropicalis, Candida guilliermondii and Candida krusei induced production of TNF-
α, IL-6 and IL1-β in PBMC co-cultures (B). Human monocyte-derived macrophages were shown to 
recognize and phagocytose C. auris (C). Anti-Als3p antibodies generated by the NDV-3A vaccine in 
mice significantly reduced biofilm formation capabilities in C. auris (D) and enhanced 
opsonophagocytic killing by murine macrophages in vitro (E). Neutropenic mice susceptible to lethal 
C. auris-disseminated infection were protected following Als3p vaccination. Depletion of 
macrophages and CD4+ T cells in this model resulted in reduced survival rates in mice, suggestive 
that these cell subsets play an important role in NDV-3A vaccine-mediated protection (F). Figure was 
created with BioRender. 
9. Concluding Remarks 
C. auris demonstrates pathogenic traits of a successful pathogen. Undoubtedly, antifungal 
resistance is the most significant benefit to this yeast, and when combined with thermotolerant and 
biofilm attributes, then its future importance to clinical mycology remains undisputed. Whether 
further distinct clades emerge from different geographical regions remains to be seen, though we are 
better prepared a decade later in our ability to react and manage these infections. The next ten years 
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will provide opportunities to develop a greater understanding of C. auris cell biology and how it 
interacts with host immunity. Moreover, as new classes of antifungals come through the pipeline, 
then novel therapies will offer some optimism for control of this yeast. Additionally, as next 
generation sequencing technologies improve, we will enhance our ability to carefully map 
interspecies and interkingdom interactions. This will enable us to determine whether C. auris 
synergises or is antagonized by co-colonising microorganisms. This may form a platform for 
alternative bio-control opportunities as suggested by recent probiotic studies [74]. 
Going forward, we must be cautious as a community not to lose perspective on the key issues in 
medical mycology. To a large extent, C. auris represents an unknown, and this has led to an intensified 
focus to understand this emergent pathogen. There are significant amounts of low hanging fruit for 
the taking, but this should not be to the detriment of understanding more important mycological 
issues, such as antifungal resistance. Compared to other Candida species, C. auris does not appear to 
have the same extensive global footprint and burden on human health, and it does not have the same 
arsenal of virulence attributes. As it stands, it remains worthy of our consideration, but whether it 
continues to dominate our attention, or simply becomes a footnote in our history, remains to be seen. 
It is difficult to predict the future for this enigmatic yeast, but we can be sure that it will preoccupy 
the mycology research community for the next decade.  
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